Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joan Albanell

Showing results (1-10 of 180) with videos related to

Pageof 18
Sort By:
Advances in Experimental Medicine and Biology|December 14, 2006
Dual/pan-HER tyrosine kinase inhibitors: focus in breast cancerJoan Albanell
Hematology/Oncology Clinics of North America|January 7, 2003
Epithelial growth factor receptor interacting agentsJose Baselga, Joan Albanell
Current Oncology Reports|June 5, 2002
Targeting epidermal growth factor receptor in lung cancerJosé Baselga, Joan Albanell
Current Drug Targets|April 29, 2005
Small molecules with EGFR-TK inhibitor activityJoan Albanell, Pere Gascón
International Journal of Clinical Pharmacy|September 8, 2014
Oral chemotherapy prescription safety practices in EuropeDavid Conde-Estévez, Joan Albanell
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Is Metastatic Disease the Best Setting for Cost-Effectiveness Studies?Ramon Colomer, Tomás Pascual, Joan Albanell
Advances in Experimental Medicine and Biology|April 19, 2020
Circulating Tumor Cells: Applications for Early Breast CancerTamara Martos, David Casadevall, Joan Albanell
BJU International|August 3, 2007
Intermittent chemotherapy in metastatic androgen-independent prostate cancerJoaquim Bellmunt, Santiago Albiol, Joan Albanell
International Journal of Clinical Pharmacy|October 17, 2013
Survey of oral chemotherapy safety and adherence practices of hospitals in SpainDavid Conde-Estévez, Esther Salas, Joan Albanell
Medicina Clinica|July 2, 2013
[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm]Alba Dalmases, Federico Rojo, Ana Rovira, et al.
Pageof 18

Showing results (1-10 of 180) with videos related to

Sort By:
Pageof 18
Advances in Experimental Medicine and Biology|December 14, 2006
Dual/pan-HER tyrosine kinase inhibitors: focus in breast cancerJoan Albanell
Hematology/Oncology Clinics of North America|January 7, 2003
Epithelial growth factor receptor interacting agentsJose Baselga, Joan Albanell
Current Oncology Reports|June 5, 2002
Targeting epidermal growth factor receptor in lung cancerJosé Baselga, Joan Albanell
Current Drug Targets|April 29, 2005
Small molecules with EGFR-TK inhibitor activityJoan Albanell, Pere Gascón
International Journal of Clinical Pharmacy|September 8, 2014
Oral chemotherapy prescription safety practices in EuropeDavid Conde-Estévez, Joan Albanell
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Is Metastatic Disease the Best Setting for Cost-Effectiveness Studies?Ramon Colomer, Tomás Pascual, Joan Albanell
Advances in Experimental Medicine and Biology|April 19, 2020
Circulating Tumor Cells: Applications for Early Breast CancerTamara Martos, David Casadevall, Joan Albanell
BJU International|August 3, 2007
Intermittent chemotherapy in metastatic androgen-independent prostate cancerJoaquim Bellmunt, Santiago Albiol, Joan Albanell
International Journal of Clinical Pharmacy|October 17, 2013
Survey of oral chemotherapy safety and adherence practices of hospitals in SpainDavid Conde-Estévez, Esther Salas, Joan Albanell
Medicina Clinica|July 2, 2013
[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm]Alba Dalmases, Federico Rojo, Ana Rovira, et al.
Pageof 18